GlassScriptPhysician profile
Schuyler Cook
NPI 1952802779
$3,966.04
in general payments reported to CMS, 2019-2025
31 companies · $652 in 2025
The $652 reported for 2025 was more than what 78% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $405 · 2022: $1,040 · 2023: $782 · 2024: $1,088 · 2025: $652.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,521.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $770.61 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $463.73 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Abbvie INC. | $409.09 | 2021-2024 | Qulipta, Vraylar, Ubrelvy |
| Bayer Healthcare Pharmaceuticals INC. | $318.54 | 2021-2024 | |
| Otsuka America Pharmaceutical, INC. | $252.82 | 2021-2025 | Rexulti |
| Phathom Pharmaceuticals, INC. | $246.45 | 2024-2025 | Voquezna |
| Pfizer INC. | $214.38 | 2022-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $184.85 | 2021-2024 | Xifaxan |
| Teva Pharmaceuticals USA, INC. | $125.88 | 2021-2022 | |
| Glaxosmithkline, LLC. | $118.67 | 2022-2025 | Shingrix, Arexvy |
| Astrazeneca Pharmaceuticals LP | $117.60 | 2021-2025 | Farxiga, Airsupra, Breztri |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $103.97 | 2024-2025 | Caplyta |
| Lundbeck LLC | $103.54 | 2024 | Rexulti |
| Kowa Pharmaceuticals America, INC. | $76.14 | 2021-2023 | Livalo, Seglentis |
| Amgen INC. | $69.96 | 2021-2023 | Otezla, Repatha |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $58.95 | 2022-2025 | Jardiance |
| Mannkind Corporation | $50.00 | 2022 | |
| Sanofi-Aventis U.S. LLC | $34.30 | 2024-2025 | |
| Dexcom, INC. | $32.00 | 2023-2024 | Dexcom G6 Transmitter |
| Sumitomo Pharma America, INC. | $26.76 | 2023 | Gemtesa |
| Corcept Therapeutics | $24.12 | 2025 | Korlym |
| Impel Pharmaceuticals INC. | $22.87 | 2022 | |
| Axsome Therapeutics, INC. | $19.84 | 2024 | Auvelity |
| Daiichi Sankyo INC. | $17.92 | 2022 | |
| Antares Pharma, INC. | $17.49 | 2021 | |
| Idorsia Pharmaceuticals US INC | $15.69 | 2023 | Quviviq |
| Takeda Pharmaceuticals U.S.A., INC. | $15.21 | 2022 | |
| Scilex Pharmaceuticals INC. | $14.57 | 2022 | |
| Sunovion Pharmaceuticals INC. | $13.95 | 2022 | |
| Janssen Pharmaceuticals, INC | $13.29 | 2023 | Xarelto |
| Tolmar, INC. | $12.85 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Schuyler Cook listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.